Physician profile

Cindy Grines

Cardiovascular Disease · Atlanta, GA

NPI 1679532311

$75,352.32

in general payments reported to CMS, 2019-2025

35 companies · $738 in 2025

The $738 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$22,131.25
Travel and Lodging$16,629.48
Food and Beverage$2,990.48
Honoraria$2,750.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk As $27,434.08 2023
Abiomed $20,869.34 2019-2023 Impella
Philips North America LLC $14,691.79 2021-2024 (9520) Igt Devices Undivided, (Bh4) Igt Devices Undivided
Boston Scientific Corporation $4,446.22 2019-2025 Watchman Flx, Avvigo Guidance System, General - Therapies
Medtronic Vascular, INC. $3,138.33 2019-2020
Novo Nordisk INC $826.61 2021-2025 Wegovy
Novartis Pharmaceuticals Corporation $631.07 2021-2025
Medtronic, INC. $407.87 2021-2025 Micra, Corevalve Evolut R
Janssen Pharmaceuticals, INC $380.17 2020-2024 Xarelto
Celonova Biosciences, INC. $362.35 2019-2020
Amgen INC. $270.56 2020-2025 Repatha, Repatha
Biotronik INC. $229.00 2022-2023 Acticor 7 Vr-T Dx
Pfizer INC. $199.48 2021-2025
Abbott Laboratories $183.54 2022-2023 Amplatzer Amulet
Shockwave Medical, INC $169.00 2020
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Amarin Pharma, INC. $132.40 2021
Bayer Healthcare Pharmaceuticals INC. $109.53 2024-2025
Tersera Therapeutics LLC $109.31 2023 Xermelo
Astrazeneca Pharmaceuticals LP $100.09 2020-2023 Farxiga
Heartflow, INC. $82.21 2019-2025
E.R. Squibb & Sons, L.L.C. $80.61 2021-2024 Eliquis, Camzyos
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $57.14 2020-2024 Lifevest
Edwards Lifesciences Corporation $54.77 2022-2025 Sapien 3 Ultra Resilia
Cvrx, INC. $53.05 2023 Barostim Neo System
Actelion Pharmaceuticals US, INC. $48.10 2021-2022
Sanofi-Aventis U.S. LLC $47.51 2023-2024
Merck Sharp & Dohme LLC $39.88 2022-2023 Verquvo
Boehringer Ingelheim Pharmaceuticals, INC. $39.05 2021-2023 Jardiance
Esperion Therapeutics, INC. $35.21 2024-2025 Nexletol
Lexicon Pharmaceuticals, INC. $30.74 2024
Scpharmaceuticals INC. $24.31 2025
Kestra Medical Technology Services, INC. $21.00 2023 Assure Wcd
Coloplast Corp $20.05 2024
Cardiva Medical, INC. $15.42 2022
Chiesi USA, INC. $12.53 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$2,689.15 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Cindy Grines

$75,352.32

in general payments reported 2019-2025

Years
2019-2025
Top company
Novo Nordisk As
Context
The $738 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/121411/cindy-grines

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.